title: CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?
authors.affiliation: Department of Pharmacoepidemiology and Pharmacotherapy, University Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. t.schalekamp@pharm.uu.nl
authors.forename: Tom
authors.initials: T
authors.lastname: Schalekamp
authors.forename: Gerard J J
authors.initials: GJ
authors.lastname: Boink
authors.forename: Loes E
authors.initials: LE
authors.lastname: Visser
authors.forename: Bruno H Ch
authors.initials: BH
authors.lastname: Stricker
authors.forename: Anthonius
authors.initials: A
authors.lastname: de Boer
authors.forename: Olaf H
authors.initials: OH
authors.lastname: Klungel
mesh_terms: D000074:Acenocoumarol / Q000008:administration & dosage / Q000009:adverse effects*; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D001778:Blood Coagulation Disorders / Q000139:chemically induced / Q000453:epidemiology / Q000235:genetics*; D003362:Cost-Benefit Analysis; D065729:Cytochrome P-450 CYP2C9; D005838:Genotype; D006801:Humans; D019934:International Normalized Ratio / Q000191:economics*; D015233:Models, Statistical; D009426:Netherlands / Q000453:epidemiology
chemical_list: D000925:Anticoagulants; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D000074:Acenocoumarol